Gastrin and upper GI cancers

Curr Opin Pharmacol. 2016 Dec;31:31-37. doi: 10.1016/j.coph.2016.08.013. Epub 2016 Aug 31.

Abstract

Gastrin was initially identified as the hormone primarily responsible for gastric acid secretion, but was subsequently shown to be a growth factor for the proximal stomach, acting through the gastrin receptor CCK2R. Studies in the past several decades have explored the role of gastrin, along with its incompletely processed precursors, in cancer development. The growth in long-term PPI use has frequently led to elevations in serum gastrin levels in patients with upper GI disease, including GERD, peptic ulcers, and chronic gastritis. However, while accumulated evidence has shown that gastrin likely does not promote-and may even suppress-distal antral gastric cancer, questions have now arisen regarding possible effects of gastrin on the development of gastric cardia cancer or esophageal adenocarcinoma at gastroesophageal junction. Here, we provide an overview of the possible roles of these gastrin peptides in upper GI cancer.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology*
  • Animals
  • Esophageal Neoplasms / pathology*
  • Esophagogastric Junction / pathology
  • Gastrins / blood
  • Gastrins / metabolism*
  • Gastrointestinal Diseases / physiopathology
  • Humans
  • Proton Pump Inhibitors / pharmacology
  • Stomach Neoplasms / pathology*

Substances

  • Gastrins
  • Proton Pump Inhibitors

Supplementary concepts

  • Adenocarcinoma Of Esophagus